<DOC>
	<DOCNO>NCT00702325</DOCNO>
	<brief_summary>To compare efficacy SYMBICORT® pMDI 160/4.5 μg x 2 actuation twice daily ( bid ) budesonide inhalation powder DPI 180 μg x 2 inhalation bid , African American ( self-reported ) subject inhale corticosteroid ( ICS ) dependent asthma .</brief_summary>
	<brief_title>Phase4/Symbicort® Versus Pulmicort Flexhaler® African Americans</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>African American ( selfreported ) Documented clinical diagnosis asthma define American Thoracic Society ( ATS ) least 6 month prior Visit 2 stable condition . FEV1 , measure ≥6 hour last dose shortacting β2agonist least 48 hour LABA , 45 % 85 % , inclusive , predict normal . Has hospitalize least asthma related condition 6 month prior Visit 2 , require emergency treatment due asthma related condition 3 month prior Visit 2 . Has require treatment systemic corticosteroid ( eg , oral , parenteral , ocular , rectal ) reason within 30 day prior Visit 2 . Has respiratory infection viral/bacterial illness , recover illness time Visit 3 , Investigator 's opinion , interfere subject 's lung function and/or ability perform spirometry</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Asthma</keyword>
</DOC>